the efficacy of mycophenolate mofetil (MMF) versus cyclophosphamide (CTX) as induction therapy for the first 6 months in pediatric patients with class III lupus nephritis (LN).IntroductionRenal involvement is one of the major determinants of the outcome in patients with systemic lupus erythematosus. ...
Purpose To study the use in real life clinical practise of glucocorticoids (GCs), immunosuppressive and adjuvant therapy in Class III-IV Lupus Nephritis (LN). Methods A multiple choice electronic questionnaire was sent to Latin American rheumatologists. Ten questions addressing the following topics: ...
Successful Treatment of Class V+IV Lupus Nephritis with Multi-Target Immunosuppressive Therapy. Journal of the American Society of Nephrology : JASNSuccessful treatment of class V IV lupus nephritis with multitarget therapy. H Bao,ZH Liu,HL Xie,WX... H Bao,HL Xie,HT Zhang,... 被引量: 51...
Nephritis in systemic lupus erythematosus is one of the manifestations of organ damage in this autoimmune disease. Class IV is the most ominous among the classes of nephritides and there are conflicting reports on whether class IV-G lupus nephritis differs from class IV-S as defined by the Int...
[15] Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis. Retrieved February 18, 2024, from https://www.businesswire.com/news/home/20240214963142/en [16] Replicate Bioscience Announces Positive Initial Clinical Results for its ...
3) Pure class V lupus nephritis 单纯性V型狼疮性肾炎 例句>> 4) Membranous lupus nephritis 膜型狼疮肾炎 1. Objective:To investigate the clinical and pathological features of Membranous lupus nephritis(MLN). 目的:总结15例膜型狼疮肾炎(MLN)患者的临床及病理特征。5) Model of Lupus Nephritis ...
Treatment of lupus nephritis (LN) remains challenging. To assess the efficacy and safety of a multitarget therapy consisting of tacrolimus, mycophenolate m... Z Liu,H Zhang,Z Liu,... - 《Annals of Internal Medicine》 被引量: 101发表: 2015年 Multitarget therapy for induction treatment of lu...
[1] KEZAR LIFE SCIENCES ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE MISSION PHASE 2 TRIAL EVALUATING ZETOMIPZOMIB FOR THE TREATMENT OF PATIENTS WITH LUPUS NEPHRITIS. Retrieved June 28, 2022 from https://ir.kezarlifescience...
Drug-induced lupus nephritis in patients treated with TNF α inhibitor is a rare adverse effect. Anti-TNF α therapies are commonly associated with the induction of auto-antibodies, whereas anti-TNF α-induced lupus is rare, most frequently involving...
pneumonitis, and nephritis … concluded that oncology healthcare providers are informed on similar … immune-mediated risks based use of ipilimumab (IPI), approved on March 25, 2011, for the treatment of … melanoma. This same rationale was applied … to not require a REMS for … pembrolizumab...